Elizaveta Dutysheva

Dr. Elizaveta Dutysheva


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MMmarina mikeladze
marina mikeladze
EDElizaveta Dutysheva
Elizaveta Dutysheva
VKViktor Georgievich Kartsev
Viktor Georgievich Kartsev
Boris MargulisBoris Margulis
Boris Margulis
IGIrina Guzhova
Irina Guzhova
VLVladimir F. Lazarev
Vladimir F. Lazarev
Hypoxia, which commonly accompanies tumor growth, depending on its strength may cause the enhancement of tumorigenicity of cancer cells or their death. One of the proteins targeted by hypoxia is glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and we demonstrated here that hypoxia mimicked by treating C6 rat glioblastoma cells with cobalt chloride caused an up-regulation of the enzyme expression, while further elevation of hypoxic stress caused the enzyme aggregation concomitantly with cell death. Reduction or elevation of GAPDH performed with the aid of specific shRNAs resulted in the augmentation of the tumorigenicity of C6 cells or their sensitization to hypoxic stress. Another hypoxia-regulated protein, Hsp70 chaperone, was shown to prevent the aggregation of oxidized GAPDH and to reduce hypoxia-mediated cell death. In order to release the enzyme molecules from the chaperone, we employed its inhibitor, derivative of colchicine. The compound was found to substantially increase aggregation of GAPDH and to sensitize C6 cells to hypoxia both in vitro and in animals bearing tumors with distinct levels of the enzyme expression. In conclusion, blocking the chaperonic activity of Hsp70 and its interaction with GAPDH may become a promising strategy to overcome tumor resistance to multiple environmental stresses and enhance existing therapeutic tools.

1 October 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
EDElizaveta Dutysheva
Elizaveta Dutysheva
IUIrina A. Utepova
Irina A. Utepova
MTMaria Trestsova
Maria Trestsova
AAAlexander S. Anisimov
Alexander S. Anisimov
Valery N. CharushinValery N. Charushin
Valery N. Charushin
VLVladimir F. Lazarev
Vladimir F. Lazarev

1 June 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
VLVladimir F. Lazarev
Vladimir F. Lazarev
EMElena Radislavovna Mikhaylova
Elena Radislavovna Mikhaylova
EDElizaveta Dutysheva
Elizaveta Dutysheva
RSRoman V. Suezov
Roman V. Suezov
IGIrina Guzhova
Irina Guzhova
Boris MargulisBoris Margulis
Boris Margulis

16 February 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
VLVladimir F. Lazarev
Vladimir F. Lazarev
EDElizaveta Dutysheva
Elizaveta Dutysheva
IKIgor E. Kanunikov
Igor E. Kanunikov
IGIrina Guzhova
Irina Guzhova
Boris MargulisBoris Margulis
Boris Margulis
The amyloid concept of Alzheimer’s disease (AD) assumes the β-amyloid peptide (Aβ) as the main pathogenic factor, which injures neural and other brain cells, causing their malfunction and death. Although Aβ has been documented to exert its cytotoxic effect in a solitary manner, there is much evidence to claim that its toxicity can be modulated by other proteins. The list of such Aβ co-factors or interactors includes tau, APOE, transthyretin, and others. These molecules interact with the peptide and affect the ability of Aβ to form oligomers or aggregates, modulating its toxicity. Thus, the list of potential substances able to reduce the harmful effects of the peptide should include ones that can prevent the pathogenic interactions by specifically binding Aβ and/or its partners. In the present review, we discuss the data on Aβ-based complexes in AD pathogenesis and on the compounds directly targeting Aβ or the destructors of its complexes with other polypeptides.

20 December 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
EDElizaveta Dutysheva
Elizaveta Dutysheva
EMElena Radislavovna Mikhaylova
Elena Radislavovna Mikhaylova
MTMaria Trestsova
Maria Trestsova
AAAlexander Andreev
Alexander Andreev
DADanila Apushkin
Danila Apushkin
VLVladimir F. Lazarev
Vladimir F. Lazarev
The recovery period after traumatic brain injury (TBI) is often complicated by secondary damage that may last for days or even months after trauma. Two proteins, Hsp70 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), were recently described as modulating post-traumatic processes, and in this study, we test them as targets for combination therapy using an inhibitor of GAPDH aggregation (derivative of hydrocortisone RX624) and an inducer of Hsp70 synthesis (the pyrrolylazine derivative PQ-29). The protective effect of the combination on C6 rat glioblastoma cells treated with the cerebrospinal fluid of traumatized animals resulted in an increase in the cell index and in a reduced level of apoptosis. Using a rat weight drop model of TBI, we found that the combined use of both drugs prevented memory impairment and motor deficits, as well as a reduction of neurons and accumulation of GAPDH aggregates in brain tissue. In conclusion, we developed and tested a new approach to the treatment of TBI based on influencing distinct molecular mechanisms in brain cells.

30 April 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
EDElizaveta Dutysheva
Elizaveta Dutysheva
MMmarina mikeladze
marina mikeladze
MTMaria Trestsova
Maria Trestsova
NANikolay Aksenov
Nikolay Aksenov
IUIrina Utepova
Irina Utepova
VLVladimir F. Lazarev
Vladimir F. Lazarev
Traumatic brain injury (TBI) often causes massive brain cell death accompanied by the accumulation of toxic factors in interstitial and cerebrospinal fluids. The persistence of the damaged brain area is not transient and may occur within days and weeks. Chaperone Hsp70 is known for its cytoprotective and antiapoptotic activity, and thus, a therapeutic approach based on chemically induced Hsp70 expression may become a promising approach to lower post-traumatic complications. To simulate the processes of secondary damage, we used an animal model of TBI and a cell model based on the cultivation of target cells in the presence of cerebrospinal fluid (CSF) from injured rats. Here we present a novel low molecular weight substance, PQ-29, which induces the synthesis of Hsp70 and empowers the resistance of rat C6 glioma cells to the cytotoxic effect of rat cerebrospinal fluid taken from rats subjected to TBI. In an animal model of TBI, PQ-29 elevated the Hsp70 level in brain cells and significantly slowed the process of the apoptosis in acceptor cells in response to cerebrospinal fluid action. The compound was also shown to rescue the motor function of traumatized rats, thus proving its potential application in rehabilitation therapy after TBI.